(435) 292-5548
 Medicare News
Home  ›  Prescription Assistance  ›  Incruse Ellipta

COPD & Asthma

Incruse Ellipta Assistance Programs & Grants

Assistance information last verified: August 2026

AltaMedicare is an independent Medicare agency in Alpine, Utah, founded by Bret Swope, a licensed Medicare agent. We provide educational, no-pressure help comparing Medicare Advantage, Medigap (Medicare Supplement), and Part D at no cost, serving the entire state of Utah. Call or text (435) 292-5548.

Manufacturer programs, charitable grants and Medicare routes for Incruse Ellipta (umeclidinium) — each checked on its official source.

Can I get help paying for Incruse Ellipta?

Yes — GSK's patient assistance program covers Incruse Ellipta with a Medicare route, subject to a $600 prescription-spending threshold for the calendar year. The COPD charitable funds that list Incruse were closed. The most practical lever here is price comparison: GSK's $134.20 cash price is the lowest of any inhaler on this site.

  • GSK Patient Assistance Program: Incruse Ellipta is on the published list of eligible products. Medicare route requires a Medicare drug plan, income at or below $47,880 for one person, and $600 already spent on prescriptions this calendar year.
  • GSK Direct to You: $134.20 cash plus a fee of up to $25 — the lowest published inhaler cash price in this registry. The federal TrumpRx site lists the same inhaler at $159.20.
  • Authorized generic: DailyMed labels "Umeclidinium Ellipta" alongside the brand.
  • NOT a Medicare-negotiated drug for 2026, 2027 or 2028 — unlike Breo, Trelegy and Anoro.
  • Charitable grants: TotalAssist's COPD fund and COPD health equity fund both list Incruse and both were closed ($1,200 guaranteed / $3,500 maximum). HealthWell's COPD – Medicare Access fund was closed. Good Days has no COPD fund.

3 of the 6 programs we checked for Incruse Ellipta were accepting applications when verified in August 2026.

About Incruse Ellipta (umeclidinium)

Incruse Ellipta is a once-daily maintenance inhaler for COPD containing one long-acting bronchodilator and nothing else. It is the simplest member of GSK's Ellipta family — Anoro is the same molecule with a second bronchodilator added, and Trelegy adds a steroid to that pair — and it is also the least expensive of the three to buy for cash.

Approved uses

  • Maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, to improve airflow

Manufacturer: GSK (GlaxoSmithKline)

Why Incruse Ellipta can be expensive on Medicare

Incruse Ellipta is a brand inhaler used every day indefinitely, and Part D plans generally put it on a brand tier. But it is the least expensive inhaler in this registry to buy outright: GSK sells it direct at $134.20, plus a processing and shipping fee of up to $25. For comparison, the same program prices Anoro Ellipta — Incruse plus a second bronchodilator — at $222.94. An authorized generic, "Umeclidinium Ellipta", is also labelled on DailyMed.

Medicare coverage context

Incruse Ellipta is an inhaler you use yourself, so Medicare covers it under Part D or a Medicare Advantage drug plan, usually on a brand tier. It is NOT a Medicare-negotiated drug: CMS's selected-drug and Maximum Fair Price file has no Incruse or umeclidinium-alone row for 2026, 2027 or 2028. That is worth stating plainly because its siblings are on those lists — Breo Ellipta and Trelegy Ellipta for 2027, Anoro Ellipta for 2028 — so it is easy to assume the whole family is covered when it is not. Part D out-of-pocket costs are capped at $2,100 in 2026, Extra Help lowers cost-sharing for people with limited income and resources, and the Medicare Prescription Payment Plan can spread what you owe across the year.

Check typical Part D coverage · Estimate your drug costs · Compare Part D drug plans

Incruse Ellipta assistance options at a glance

Every program we checked, what kind of help it is, whether people with Medicare can use it, and its status when we verified it. A medication being listed by a program is not the same as the program accepting applications.

About the income limits below: Income limits can differ between assistance programs even when both describe their eligibility as the same percentage of the federal poverty level. The dollar limits shown here come from each program's own published income table, and each program decides which year's poverty guidelines that table is built from and when it takes effect. Treat the figures as belonging to the program they are listed under — they are not interchangeable, and only the program can tell you which table it is applying to your application today.

Incruse Ellipta assistance programs compared
ProgramType of helpPeople with MedicareStatus (August 2026)
GSK Patient Assistance Program Manufacturer patient assistance with conditions Accepting applications
GSK Direct to You (cash price) Manufacturer self-pay pricing with conditions Accepting applications
Incruse Ellipta dollars-off coupon Commercial copay / savings card not eligible Open with limits
TotalAssist — COPD funds Charitable grant may apply Closed to new applicants
HealthWell Foundation — COPD – Medicare Access fund Charitable grant may apply Closed to new applicants
Good Days — no applicable fund Charitable grant not stated No program found
Medicare Extra Help (Part D Low-Income Subsidy) Government program may apply Accepting applications

Manufacturer programs from GSK (GlaxoSmithKline)

A patient assistance program (free or low-cost drug by income) is not the same as a copay card (a commercial discount that usually excludes Medicare). Both are listed so you can see which one applies to you.

Manufacturer patient assistance

GSK Patient Assistance Program

GSK Patient Access Programs Foundation (an independent 501(c)(3) charitable foundation)

Accepting applications Medicare: with conditions

Status: Accepting applications on August 26, 2026. Incruse Ellipta appears on the program's published "List of eligible products".

The GSK Patient Access Programs Foundation supplies certain GSK medicines at no cost to people who meet its income and insurance rules. Incruse Ellipta is one of them.

If you have Medicare: Medicare beneficiaries may apply through GSK's Medicare route for "general" category medicines, which is where Incruse Ellipta sits. You must have a Medicare prescription drug plan and "have paid a total of $600 for prescriptions in the current calendar year", and your income must be at or below the program's table. Note that GSK applies different Medicare rules to its specialty medicines — Nucala has no spending threshold but excludes Extra Help enrollees — so check the rule for the medicine you are actually applying for.

What it can cover: Incruse Ellipta at no cost to approved patients, supplied through the program.

Who may qualify

  • Live in the United States or Puerto Rico
  • Have a Medicare prescription drug plan and meet the program's other requirements
  • Have paid a total of $600 for prescriptions in the current calendar year
  • Maximum annual gross income (48 states and DC): $47,880 for one person, $64,920 for two, $81,960 for three, $99,000 for four, adding $17,040 for each additional person
  • Higher limits apply in Alaska ($59,850 for one person) and Hawaii ($55,080); Puerto Rico limits are lower ($28,800)
  • Not eligible for Puerto Rico's Government Health Plan Mi Salud, or have applied and been denied

What the application asks for

  • Proof of household income
  • Your Medicare prescription drug plan details
  • Records of prescription spending this calendar year, for the $600 threshold
  • Your prescriber's details — GSK enrollment forms are signed by both patient and provider

How to apply

Start at the GSK Patient Assistance Program page and follow the Medicare route for prescription medicines. Both you and your prescriber sign the enrollment form. Call 1-866-728-4368 with questions or to have a form mailed.

GSK Patient Assistance — Medicare eligibility → 1-866-728-4368

Manufacturer self-pay pricing

GSK Direct to You (cash price)

GSK, dispensed by Alto Pharmacy

Accepting applications Medicare: with conditions

Status: Available on August 26, 2026 with Incruse Ellipta priced at $134.20, plus "a processing and shipping fee of up to $25" per order.

The most useful number on this page for many readers. $134.20 is a real, published, manufacturer-set cash price, and it is the benchmark to measure your plan's copay or coinsurance against.

If you have Medicare: GSK states: "This Offer is not available to patients who wish to use insurance." A Medicare beneficiary may still buy this way by paying cash outside the Part D benefit — but that spending will not count toward your plan's deductible or the annual out-of-pocket cap, so it is only worth doing if the cash price genuinely beats your plan's cost-sharing. GSK's own advice on the page is "If you have insurance, check with your pharmacy, your price may be lower."

What it can cover: The medication at the published price, shipped to you. Not insurance and not a copay reduction.

Who may qualify

  • Not using prescription insurance for this fill
  • A valid prescription sent by your healthcare provider

How to apply

Your provider sends the prescription to the program pharmacy; Alto Pharmacy confirms receipt and guides you through the next steps. Call Alto on (800) 874-5881.

GSK Direct to You prices → (800) 874-5881

Commercial copay / savings card

Incruse Ellipta dollars-off coupon

GSK

Open with limits Medicare: not eligible

Status: Listed on GSK's coupons page on August 26, 2026. GSK publishes no dollar value — the amount appears only through the site's coupon finder — so no figure is reproduced here.

A commercial discount for people with private or employer prescription insurance. Not a route for anyone with Medicare.

If you have Medicare: GSK's terms: the coupon "may not be used by government beneficiaries, including but not limited to those enrolled in Medicare or Medicaid." There is also no GSK copay program for Incruse — that list covers seven specialty and oncology medicines and no Ellipta inhaler.

Who may qualify

  • Commercial (private or employer-sponsored) prescription insurance
  • Not enrolled in Medicare, Medicaid or another government prescription program

How to apply

Commercially insured patients can use the coupon finder on GSK's coupons page. Medicare beneficiaries should use the patient assistance program or compare the cash price.

GSK coupons and offers →

Charitable grants for Incruse Ellipta

Incruse Ellipta sits on the same charitable funds as the rest of the GSK COPD family and, on August 26, 2026, they were all closed. TotalAssist lists it on the COPD fund and the COPD health equity fund, each paying $1,200 guaranteed up to $3,500; HealthWell's COPD – Medicare Access fund was closed as well; Good Days runs no COPD fund at all. Because the charitable side is shut, the routes that actually move money for this medication are the ones that do not depend on a fund balance: GSK's patient assistance program, the authorized generic, Extra Help, and the $134.20 cash price — which for Incruse is a genuinely competitive number rather than a last resort. Set alerts on both foundations so you hear if a fund reopens.

Charitable grant

TotalAssist — COPD funds

Patient Advocate Foundation · Chronic obstructive pulmonary disease (COPD) · COPD health equity

Closed to new applicants Medicare: may apply

Status: Both COPD funds were closed to new applicants on August 26, 2026, each with a $1,200 guaranteed and $3,500 maximum award. TotalAssist has no waitlist, so the notification sign-up is what gets you in.

"Incruse Ellipta (Umeclidinium Bromide)" is named on the COPD approved-medication list, as are the other Ellipta inhalers and a long list of generics. Both applicable funds were closed when we checked.

If you have Medicare: These funds require government-insured coverage — Medicare, Medicaid or TRICARE — that covers your qualifying expenses. Medicare beneficiaries are eligible when a fund is open.

What it can cover: When open: $1,200 guaranteed award and up to $3,500 maximum for medication copays, coinsurance, deductibles and health-insurance premiums. One grant per condition.

Who may qualify

  • Confirmed COPD diagnosis, in treatment, starting within 60 days, or treated in the past 6 months
  • Government-insured coverage (Medicare, Medicaid or TRICARE) that covers your qualifying expenses
  • Household income at or below 500% of the federal poverty level, adjusted for your regional cost-of-living index
  • Confirmed diagnosis matching the fund, and in treatment (or starting within 60 days, or treated in the past 6 months)
  • Legal U.S. resident receiving treatment in the U.S. or a U.S. territory
  • The health-equity fund additionally requires a home zip code in a designated social-vulnerability county

What the application asks for

  • Contact information and Social Security number (or alien number)
  • Annual household income (for pre-screening; proof of income due within 30 days of approval)
  • Health insurance carrier, plan type, policy ID and group number; Medicare supplement or secondary insurance if you have one
  • Copay or coinsurance amounts
  • Your provider's name and contact information, diagnosis (exact date if within 6 months), prescribed medications and treatment plan

How to apply

Sign up for fund notifications (text, email or automated call) at totalassist.org/notify. When a fund opens: You (the patient) apply online — it takes about 15 minutes and you learn immediately whether you are approved — or call 866-512-3861, Monday–Friday 8:30am–5:30pm ET. Patient Advocate Foundation verifies your diagnosis and treatment plan directly with your provider and verifies income automatically; you have 30 days after approval to provide proof of income.

Get notified when a TotalAssist fund opens → 866-512-3861

Charitable grant

HealthWell Foundation — COPD – Medicare Access fund

HealthWell Foundation · Chronic Obstructive Pulmonary Disease – Medicare Access

Closed to new applicants Medicare: may apply

Status: Closed on August 26, 2026. The only open lung fund on HealthWell's published list was Bronchiectasis, a different diagnosis.

HealthWell runs a COPD fund designed for Medicare beneficiaries; it was closed when we checked. HealthWell says replenished funds reopen as quickly as possible and offers real-time alerts.

If you have Medicare: A "Medicare Access" fund — built specifically for people with Medicare — which makes it worth an alert even while closed.

What it can cover: When open: copays, coinsurance, deductibles and health-insurance premiums for COPD.

Who may qualify

  • A confirmed COPD diagnosis, verified by your prescriber
  • Some form of health insurance (Medicare qualifies) that covers part of the cost of the drug — discount cards do not count
  • Social Security number (used to prevent duplicate applications)
  • Diagnosis verified by a physician's, nurse practitioner's or physician assistant's signature
  • Treatment in the United States

What the application asks for

  • Some form of health insurance (Medicare qualifies) that covers part of the cost of the drug — discount cards do not count
  • Social Security number (used to prevent duplicate applications)
  • Diagnosis verified by a physician's, nurse practitioner's or physician assistant's signature
  • Treatment in the United States

How to apply

When a fund is open, apply online or by phone; your provider verifies the diagnosis by signature. When a fund is closed, sign up for that fund's real-time alerts — HealthWell says replenished funds reopen "as quickly as possible."

HealthWell disease funds and alerts → (800) 675-8416

Charitable grant

Good Days — no applicable fund

Good Days

No program found Medicare: not stated

Status: Good Days' published disease list on August 26, 2026 contained 57 programs and none of them was COPD.

An honest negative, checked so you do not spend time on a third foundation that has no fund for you.

If you have Medicare: Good Days accepts Medicare beneficiaries for the diseases it covers, but it covers no diagnosis that applies to Incruse Ellipta.

How to apply

Not applicable today. The diseases-covered page shows every fund Good Days runs.

Good Days diseases covered →

How to apply for Incruse Ellipta assistance

  1. Step 1 — Find the applicable assistance program

    Incruse has a real manufacturer program and the cheapest published cash price of any inhaler on this site. Work them in this order:

    • Limited income and $600 already spent on prescriptions this year → the GSK Patient Assistance Program.
    • Limited income and resources → Medicare Extra Help through Social Security.
    • Ask your prescriber and plan about the authorized generic, umeclidinium.
    • Compare your plan's cost-sharing against the $134.20 GSK cash price — for a lower-priced inhaler this comparison flips more often than people expect.
    • COPD diagnosis → set alerts on the TotalAssist and HealthWell COPD funds (all closed when checked).

  2. Step 2 — Check whether applications are currently open

    One manufacturer program, three charitable funds, one cash price.

    • GSK Patient Assistance: the eligible-products list and the Medicare eligibility page are authoritative and both are cited here.
    • TotalAssist: the COPD and COPD health equity fund pages show "Open" or "Closed" and the current award amounts.
    • HealthWell: the disease-funds list shows the COPD – Medicare Access fund and its status.
    • GSK Direct to You: prices are published on the program page and can change without notice.

  3. Step 3 — Check eligibility

    The GSK spending threshold is the gate most people do not expect:

    • GSK Patient Assistance: a Medicare drug plan; income at or below $47,880 for one person or $64,920 for two in the 48 states and DC; and $600 already paid for prescriptions this calendar year.
    • TotalAssist (when open): government insurance covering Incruse; income at or below 500% FPL adjusted for your regional cost-of-living index; a confirmed COPD diagnosis in treatment.
    • HealthWell (when open): insurance that covers part of the drug's cost, a prescriber-verified COPD diagnosis, and treatment in the United States.
    • GSK Direct to You: no income test — the only condition is that you are not using insurance for that fill.
    • Extra Help: income below about $23,940 a year for one person or $32,460 for a couple, and countable resources limited to $18,090 or $36,100 in 2026.

  4. Step 4 — Gather your information

    What each route will ask for:

    • Medicare card and your Part D or Medicare Advantage drug-plan card, with policy ID and group number.
    • Your prescription spending so far this calendar year, for GSK's $600 threshold.
    • Household size and annual gross income, plus proof.
    • Your COPD diagnosis and its date. TotalAssist needs the exact date if it was within the past 6 months.
    • Your prescriber's name, office address and phone.

  5. Step 5 — Complete the application

    Who fills out what:

    • GSK Patient Assistance: both you and your prescriber sign the enrollment form.
    • Extra Help: you (or someone helping you) apply free through Social Security — online, by phone on 1-800-772-1213, or at an office. There is never a fee.
    • TotalAssist (when open): you apply online in about 15 minutes or by phone on 866-512-3861.
    • HealthWell (when open): apply online or by phone; your provider verifies the diagnosis by signature.
    • GSK Direct to You: your provider sends the prescription; Alto Pharmacy contacts you.

  6. Step 6 — Submit and wait for a determination

    What to expect:

    • GSK Patient Assistance: the foundation reviews income and insurance documentation; approved medicine is supplied through the program.
    • Extra Help: Social Security notifies you by mail; your plan then applies the lower copays.
    • TotalAssist (when open): an immediate online decision, with proof of income due within 30 days of approval.
    • GSK Direct to You: no determination — it is a purchase, not an application.

  7. Step 7 — If the program is closed or you don't qualify

    For a medication at this price point, the cash comparison is usually the answer:

    • Ask about the authorized generic — DailyMed labels "Umeclidinium Ellipta" alongside GSK's brand.
    • Run the numbers on $134.20 (GSK Direct to You, plus a fee of up to $25) or $159.20 (TrumpRx) against your plan's copay or coinsurance. Remember that cash spending does not count toward your Part D out-of-pocket cap.
    • If the $600 threshold is blocking you, it is a calendar-year test that resets and is easier to meet later in the year.
    • Do not wait for a Medicare negotiated price on this one — Incruse is not on any CMS selected-drug list, even though Breo, Trelegy and Anoro are.
    • Use the Medicare Prescription Payment Plan to spread this year's out-of-pocket costs across monthly payments.
    • Call AltaMedicare — we will work through every route above with you, free.

What you'll need

Only items the programs above actually ask for. Gather these before you start.

  • Medicare card and your Part D or Medicare Advantage drug-plan card — plan name, member ID and group number
  • Prescription details — medication name, strength and dose; prescriber name, office phone and address
  • Diagnosis and date of diagnosis — TotalAssist needs the exact date if diagnosed within the past 6 months
  • Household size and annual household income — and proof — tax return, Social Security or pension statements, or pay stubs
  • Proof of prescription spending this calendar year — GSK's Medicare route requires $600 already paid — plan Explanation of Benefits statements or a pharmacy year-to-date printout
  • Confirmation that the prescription is for COPD — Incruse is not indicated for asthma, and the charitable funds are diagnosis-specific

If assistance is unavailable

A closed fund or a denial is not the end of the road. Check these next:

  1. Compare the published cash prices against your plan before assuming insurance is cheaper: GSK Direct to You lists Incruse Ellipta at $134.20 plus a fee of up to $25, and the federal TrumpRx site lists it at $159.20. GSK Direct to You
  2. Ask your prescriber and plan about the authorized generic — DailyMed labels "Umeclidinium Ellipta" alongside GSK's brand.
  3. Sign up for TotalAssist fund notifications so you hear the moment a Incruse Ellipta fund reopens — there is no waitlist or queue, so speed matters. TotalAssist notifications
  4. Sign up for HealthWell fund alerts for the same reason; HealthWell says closed funds reopen as funding is replenished. HealthWell disease funds
  5. Check Medicare Extra Help — it does not depend on a fund balance and lowers the cost of every covered drug, not just this one. Medicare Extra Help explained
  6. Ask your doctor's office — many practices have staff who handle assistance applications routinely and can request a formulary exception or a lower-cost alternative.
  7. Use the Medicare Prescription Payment Plan to spread this year's out-of-pocket costs across monthly payments (it does not lower the total). Medicare.gov
  8. Compare Part D and Medicare Advantage drug plans during the fall enrollment period — the tier and cost-sharing for Incruse Ellipta differ from plan to plan. Compare Part D plan options

Could Medicare Extra Help reduce your Incruse Ellipta costs?

Extra Help is not a grant for Incruse Ellipta. It is a Medicare program that lowers what qualifying beneficiaries pay for their Part D premium, deductible and every covered prescription — so it is worth checking even when a charitable fund is closed, because it does not depend on fund balances.

Extra Help and the GSK program can be held together — GSK's Medicare route for Incruse gates on the $600 prescription-spending threshold, not on your subsidy status. Apply for Extra Help on its own merits: with full Extra Help a covered brand-name drug costs about $12.65 in 2026, which is well below even the $134.20 cash price for a month of Incruse.

In 2026, people with full Extra Help generally pay no more than $12.65 for a covered brand-name drug. Income must be below about $23,940 a year for one person ($32,460 for a couple) and countable resources under $18,090 ($36,100 for a couple). Apply free through Social Security — online, by phone at 1-800-772-1213, or in person — and never pay anyone to apply for you.

Extra Help explained · Medicare Savings Programs · Estimate your drug costs · Free prescription cost review

Government program

Medicare Extra Help (Part D Low-Income Subsidy)

Medicare / Social Security Administration

Accepting applications Medicare: may apply

Status: Year-round federal program (figures for 2026)

Not a grant for one drug — a Medicare program that lowers what qualifying beneficiaries pay for their Part D premium, deductible and every covered prescription.

If you have Medicare: For people with Medicare Part D or a Medicare Advantage drug plan who have limited income and resources.

What it can cover: Part D premium and deductible (often to $0) and reduced copays — generally no more than $12.65 for a covered brand-name drug in 2026 with full Extra Help.

Who may qualify

  • Income below 150% of the federal poverty level — about $23,940 a year for one person or $32,460 for a married couple in 2026.
  • Countable resources (savings, investments — not your home or car) limited to $18,090 for an individual or $36,100 for a married couple living together in 2026 (Medicare.gov figures, which include a burial-expense allowance).
  • Automatic if you have Medicaid, Supplemental Security Income (SSI), or a Medicare Savings Program.

What the application asks for

  • Social Security number and Medicare number
  • Income (Social Security, pensions, wages) for you and a spouse you live with
  • Value of savings, investments and other countable resources

How to apply

You (or someone helping you) apply free through Social Security — online, by phone, or at a Social Security office. There is never a fee to apply.

Apply for Extra Help at SSA.gov → 1-800-772-1213

Key terms on this page

Patient assistance program (PAP)
A manufacturer program that provides its medication free or at low cost to people who meet income and insurance rules. Many PAPs accept Medicare Part D enrollees; each sets its own criteria.
Copay card / savings card
A manufacturer discount for commercially insured patients. Federal anti-kickback rules mean these cards generally cannot be used with Medicare, Medicaid or other government insurance.
Charitable copay grant
Money from a nonprofit foundation (for example HealthWell or Patient Advocate Foundation) that pays eligible copays or coinsurance for a specific diagnosis. A drug can be listed while the fund is closed to new applicants.
Federal poverty level (FPL)
A federal income measure that assistance programs use as a yardstick — "300% of FPL", "500% of FPL". The percentage is a rule, but the dollar figure behind it comes from a table each program publishes itself, built on a chosen year of the HHS poverty guidelines. Two programs can quote the same percentage in the same year and still list different dollar limits; compare each program against its own table, not against another program.
Medicare Extra Help
The Part D Low-Income Subsidy: a Medicare program that lowers or eliminates Part D premiums, deductibles and copays for beneficiaries with limited income and resources. You apply through Social Security.
Maximum Fair Price (MFP)
The price Medicare negotiated for a selected drug under the Medicare Drug Price Negotiation Program. It applies to Part D plans, not to the pharmacy cash price, and it lowers what plans and enrollees pay for that drug.

Related medication assistance guides

Anoro Ellipta Assistance & Grants umeclidinium / vilanterol Breo Ellipta Assistance & Grants fluticasone furoate / vilanterol Spiriva Assistance & Grants tiotropium bromide Trelegy Ellipta Assistance & Grants fluticasone furoate / umeclidinium / vilanterol All prescription assistance Directory & program finder
Common Questions

Incruse Ellipta assistance FAQ

Does Medicare cover Incruse Ellipta?
Yes — Medicare Part D and Medicare Advantage drug plans generally cover Incruse Ellipta, usually on a brand tier. Part D out-of-pocket costs are capped at $2,100 in 2026. If your income and resources are limited, Medicare Extra Help can bring a covered brand-name copay to about $12.65.
Is there an Incruse Ellipta patient assistance program for people on Medicare?
Yes. Incruse Ellipta is on the GSK Patient Assistance Program's published list of eligible products and the program has a Medicare route. The requirement people miss is the spending threshold: for GSK's "general" medicines, which includes Incruse, you must have "paid a total of $600 for prescriptions in the current calendar year". You also need a Medicare drug plan and income at or below $47,880 for one person in the 48 states and DC.
Is Incruse Ellipta part of Medicare drug price negotiation?
No, and this is worth checking rather than assuming, because three of its close relatives are. CMS's selected-drug file has no Incruse Ellipta or umeclidinium-alone row for 2026, 2027 or 2028. Breo Ellipta and Trelegy Ellipta were selected for initial price applicability year 2027, and Anoro Ellipta for 2028 — but Incruse was not selected in any cycle. Your cost is set by your plan's tier and cost-sharing.
How is Incruse Ellipta different from Anoro Ellipta?
Incruse contains one long-acting bronchodilator, umeclidinium. Anoro contains the same umeclidinium plus a second bronchodilator, vilanterol. Neither contains a steroid, and both are licensed for COPD only. The practical differences for cost are real: GSK sells Incruse direct at $134.20 and Anoro at $222.94, Anoro has been selected for Medicare price negotiation in 2028 and Incruse has not, and each has its own authorized generic. The GSK assistance program and the charitable funds treat them the same way.
Should I buy Incruse Ellipta with cash instead of using Medicare?
It is worth checking, and more often worth it here than for pricier inhalers. GSK sells Incruse direct at $134.20 plus a processing and shipping fee of up to $25; the federal TrumpRx site lists it at $159.20, which is the same price with the fee included. GSK's terms say the offer "is not available to patients who wish to use insurance", and cash spending will not count toward your Part D deductible or annual out-of-pocket cap. If your plan charges coinsurance on a brand tier, compare carefully.
Is there a generic for Incruse Ellipta?
Yes, an authorized generic. DailyMed lists five labelled umeclidinium products across two labelers, including "Umeclidinium Ellipta" alongside GSK's Incruse Ellipta. Whether it lowers your copay depends on your plan's formulary, so ask your prescriber and plan directly. See all prescription assistance options.

Sources

Related resources

Assistance information last verified August 2026. Program details — fund status, eligibility, prices, phone numbers — change often; confirm with each program before applying. AltaMedicare does not administer, fund or approve any assistance program. Not medical advice.

Having trouble figuring out your prescription costs?

Bret can help you understand your Medicare prescription coverage and where to look for Incruse Ellipta assistance — free, no pressure. We don't award grants or decide eligibility; the programs above do. We help you find and apply to the right ones.

Text Bret About Incruse Ellipta Call (435) 292-5548